The FDA approved oral ivermectin under the brand name Stromectol on November 22, 1996, for human treatment of specified parasitic infections, including intestinal strongyloidiasis and onchocerciasis.
True
The FDA approved ivermectin in 1996 to treat parasitic infections in humans under the brand name Stromectol.
Understanding Ivermectin for Parasitic Infections
Source: webmd.com
At a glance
Verified September 4, 2026Key Evidence
The FDA records Stromectol's approval date as November 22, 1996.
FDA records identify Stromectol as oral ivermectin for treating intestinal strongyloidiasis and onchocerciasis, both parasitic infections in humans.
Independent summaries from WebMD and PolitiFact agree that the FDA approved ivermectin for certain human parasitic infections, not for COVID-19.
The reporting
What the Evidence Shows
The claim is supported by an FDA clinical pharmacology review, which records that oral ivermectin, marketed as Stromectol, received approval on November 22, 1996, under New Drug Application 50-742 for intestinal strongyloidiasis, an infection caused by the parasite Strongyloides. FDA prescribing information also identifies Stromectol as an antiparasitic medicine and describes its use for onchocerciasis, commonly known as river blindness.fda.govfda.govClinical Pharmacology Review NDA #: 202736 Submission Date: April 07, 2011
Primary trail
Verified Sources10
Open source